| Literature DB >> 33997014 |
Jiangtao Chu1, Shun He1, Yan Ke1, Xudong Liu1, Peng Wang2, Wei Zhang2, Guotong Qiu2, Chengfeng Wang2, Jianwei Zhang2, Guiqi Wang1.
Abstract
BACKGROUND: The necessity of preoperative biliary drainage (PBD) prior to pancreaticoduodenectomy (PD) is still controversial. However, in some settings, PBD with endoscopic retrograde cholangiopancreatography (ERCP) procedure is recommended as a preferred management. Meanwhile, pancreatic duct stenting in the drainage procedure is rarely performed for selected indications, and its associated complications after PD remain quite unknown.Entities:
Mesh:
Year: 2021 PMID: 33997014 PMCID: PMC8105100 DOI: 10.1155/2021/5572395
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Complication criteria.
| Grade definition |
| 0: no complications |
| 1: Oral medications or supportive care |
| 2: IV medical therapy with resolution or antibiotics or specialized nutritional support |
| 3: interventional radiology, endoscopic, or operative intervention |
| 4: chronic deficit or disability associated with sequelae of this event |
| 5: death associated with sequelae of this event |
Demographic and clinical characteristics of patients NPS group and PS group.
| [ALL] | NPS∗ | PS∗ |
| |
|---|---|---|---|---|
|
|
|
| ||
| Sex (female) | 42 (50.6%) | 24 (44.4%) | 18 (62.1%) | 0.193 |
| Age | 58.0 [51.5; 63.0] | 57.0 [51.0; 62.8] | 59.0 [53.0; 63.0] | 0.436 |
| #BMI | 0.684 | |||
| Fat | 35 (42.2%) | 24 (44.4%) | 11 (37.9%) | |
| Low | 4 (4.82%) | 2 (3.70%) | 2 (6.90%) | |
| Normal | 44 (53.0%) | 28 (51.9%) | 16 (55.2%) | |
| Biliary drainage | 1.000 | |||
| ENBD | 66 (79.5%) | 43 (79.6%) | 23 (79.3%) | |
| Metal biliary stent | 1 (1.20%) | 1 (1.85%) | 0 (0.00%) | |
| Plastic bile duct stent | 16 (19.3%) | 10 (18.5%) | 6 (20.7%) | |
| Tumor location | 0.024 | |||
| Ampulla | 31 (37.3%) | 26 (48.1%) | 5 (17.2%) | |
| Bile duct | 22 (26.5%) | 12 (22.2%) | 10 (34.5%) | |
| Duodenum | 14 (16.9%) | 9 (16.7%) | 5 (17.2%) | |
| Pancreas | 16 (19.3%) | 7 (13.0%) | 9 (31.0%) | |
| Stay time | 18.0 [14.0; 22.5] | 20.0 [14.0; 23.0] | 17.0 [15.0; 22.0] | 0.681 |
| Blood transfusion | 300 [0.00; 750] | 0.00 [0.00; 675] | 500 [0.00; 800] | 0.070 |
| Operation duration | 366 [306; 454] | 359 [314; 466] | 369 [300; 432] | 0.909 |
Outcomes of patients' PS group and NPS group.
| [all] | NPS∗ | PS∗ |
| |
|---|---|---|---|---|
|
|
|
| ||
| Complication criteria | 0.57 | |||
| None | 26 (31.3%) | 15 (27.8%) | 11 (37.9%) | |
| Mild | 42 (50.6%) | 28 (51.9%) | 14 (48.3%) | |
| Severe | 15 (18.1%) | 11 (20.4%) | 4 (13.8%) | |
| Bile anastomotic leakage | 7 (8.43%) | 4 (7.41%) | 3 (10.3%) | 0.691 |
| Bleeding | 0.846 | |||
| Blood transfusion | 11 (13.3%) | 8 (14.8%) | 3 (10.3%) | |
| Dead | 2 (2.41%) | 2 (3.70%) | 0 (0.00%) | |
| Hemostasis | 3 (3.61%) | 2 (3.70%) | 1 (3.45%) | |
| None | 67 (80.7%) | 42 (77.8%) | 25 (86.2%) | |
| Abdominal infection | 0.670 | |||
| Interventional therapy | 10 (12.0%) | 8 (14.8%) | 2 (6.90%) | |
| Medication | 24 (28.9%) | 15 (27.8%) | 9 (31.0%) | |
| None | 49 (59.0%) | 31 (57.4%) | 18 (62.1%) | |
| Surgical wound infection | 13 (15.7%) | 8 (14.8%) | 5 (17.2%) | 0.761 |
| Gastrointestinal dysfunction | 9 (10.8%) | 3 (5.56%) | 6 (20.7%) | 0.060 |
| Organ dysfunction | 6 (7.23%) | 5 (9.26%) | 1 (3.45%) | 0.660 |
| Pancreatic anastomotic leakage | 0.380 | |||
| None | 58 (69.9%) | 36 (66.7%) | 22 (75.9%) | |
| A | 8 (9.64%) | 7 (13.0%) | 1 (3.45%) | |
| B | 17 (20.5%) | 11 (20.4%) | 6 (20.7%) |
The univariate and multivariate analysis of predictive factors for postoperative delayed gastric emptying.
| [ALL] | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
|
| OR |
| OR |
| |
| Sex (male) | 41 (49.4%) | 2.16 [0.51;11.5] | 0.313 | ||
| Age | 58.0 [51.5; 63.0] | 1.07 [0.98; 1.18] | 0.085 | 1.07 [0.97; 1.17] | 0.146 |
| BMI | 0.310 | ||||
| Fat | 35 (42.2%) | Ref. | |||
| Low | 4 (4.82%) | NA | |||
| Normal | 44 (53.0%) | NA | |||
| Stay time | 18.0 [14.0; 22.5] | 0.99 [0.93; 1.06] | 0.924 | ||
| Tumor location | 0.522 | ||||
| Ampulla | 31 (37.3%) | Ref. | |||
| Bile duct | 22 (26.5%) | 3.05 [0.51; 26.7] | |||
| Duodenum | 14 (16.9%) | 2.36 [0.22; 25.0] | |||
| Pancreas | 16 (19.3%) | 1.02 [0.03; 13.6] | |||
| Blood transfusion | 414 (490) | 1.00 [1.00; 1.00] | 0.145 | ||
| Operation duration | 366 [306; 454] | 1.00 [1.00; 1.01] | 0.524 | ||
| Biliary drainage | 1.000 | ||||
| ENBD | 66 (79.5%) | Ref. | |||
| Metal biliary stent | 1 (1.20%) | NA | |||
| Plastic bile duct stent | 16 (19.3%) | NA | |||
| PDS | 29 (34.9%) | 4.25 [0.99; 22.9] | 0.0472 | 4.36 [0.97; 19.42] | 0.053 |
| Bile leakage | 7 (8.43%) | 1.000 | |||
| Bleeding | 0.636 | ||||
| Blood transfusion | 11 (13.3%) | Ref. | |||
| Dead | 2 (2.41%) | NA | |||
| Hemostasis | 3 (3.61%) | NA | |||
| None | 67 (80.7%) | NA | |||
| Abdominal infection | 1.000 | ||||
| Interventional therapy | 10 (12.0%) | Ref. | |||
| Medication | 24 (28.9%) | 0.78 [0.06; 26.7] | |||
| None | 49 (59.0%) | 1.14 [0.16; 32.2] | |||
| Surgical wound infection | 13 (15.7%) | 0.72 [0.03; 4.63] | 1.000 | ||
| Organ dysfunction | 6 (7.23%) | 1.000 | |||
| Pancreatic leakage | 0.866 | ||||
| 0 | 58 (69.9%) | Ref. | |||
| A | 8 (9.64%) | NA | |||
| B | 17 (20.5%) | NA | |||